TG Therapeutics, Inc. (TGTX) fair value analysis
Nasdaq · Updated 2026-10-19
TGTX price how computed
Valuation status
No verdict this weekTGTX: Next year's consensus is far above both what this company earned over the last four quarters and what its most recent quarter is earning.
Our model does not publish a verdict on a forecast that far from results; it is re-evaluated weekly.
- Last price
- $53.97
- Sector
- Healthcare
- 12-month range
- $26.94–$59.06
- Market cap
- $8.26B
- From 52-week high
- -8.6%
- Shares outstanding
- 153M
- Rank in Healthcare by quality score
- #129 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
TG Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes novel treatments for patients with cancer and autoimmune diseases. The company operates in the United States and conducts its business as a publicly traded entity on the Nasdaq stock exchange.
TGTX currently ranks #129 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $8.26B
- P/E (trailing)
- 102x
- Revenue (TTM)
- $800M
- Net margin
- 55.2%
- EPS (TTM)
- $0.53
- Gross margin
- 82.9%
- Debt / equity
- 1.25
- Revenue growth (3-yr avg)
- 15.0%
- Shares outstanding
- 153M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 44 · neutral
- 50-day average
- $54.14
- 200-day average
- $42.49
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-02
- Last 8 quarters vs consensus
- 1 beat, 7 missed
- Quarter by quarter
- 2026-06 ▼ miss (-87.8%)
2026-03 ▼ miss (-35.7%)
2025-12 ▼ miss (-60.0%)
2025-09 ▼ miss (-27.3%)
2025-06 ▼ miss (-41.4%)
2025-03 ▼ miss (-82.4%)
2024-12 ▲ beat (+66.7%)
2024-09 ▼ miss (-33.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 0 hold · 1 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $69.7
- Target vs last price
- +29.1%
What our data shows for TGTX
- Our model validated 7 trailing price-to-earnings windows for TGTX, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $26.94–$59.06.
- The 14-day relative strength index sits at a neutral 44.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TGTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TGTX news
TickrTrends' derived news-sentiment signal for TGTX is currently leaning positive, computed from recent coverage.
- TG Therapeutics (TGTX) Showcases Long-Term MS Trial Data and Advances at ACTRIMS-ECTRIMS 2026 (gurufocus.com, 2026-10-21)
TickrTrends take: TG Therapeutics operates in the Healthcare sector, where clinical trial progress and efficacy data significantly influence investor perception of long-term commercial potential. The company's presentation of long-term multiple sclerosis trial data at ACTRIMS-ECTRIMS 2026 provides the market with additional information to assess whether current clinical outcomes support or challenge its valuation position. TickrTrends' current assessment rates TGTX as undervalued, so investors focused on valuation metrics should monitor how this trial data influences analyst price targets and institutional positioning in the coming months. - TG Therapeutics (TGTX) Reports Five-Year Study Showing BRIUMVI's Superior Disability Progression Outcomes in RMS (gurufocus.com, 2026-10-12)
TickrTrends take: TG Therapeutics operates in the Healthcare sector where long-term clinical evidence can substantively influence market valuation. The five-year study demonstrating BRIUMVI's superior outcomes in managing disability progression represents the type of clinical data that typically supports pricing power and market positioning for therapeutic companies. Given TickrTrends' current Undervalued assessment, investors focused on valuation metrics should monitor whether this clinical evidence translates into market share gains and revenue growth that would justify upward price movement toward fair value. - TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade) (NASDAQ:TGTX) (seekingalpha.com, 2026-08-26)
TickrTrends take: TG Therapeutics operates in the Healthcare sector where product lifecycle trajectories significantly influence long-term valuation outcomes. Given TickrTrends' current assessment of undervaluation, an analyst noting that Briumvi's peak sales potential may be distant suggests the market may not be fully pricing in the drug's extended revenue runway. Valuation-focused investors should monitor whether Briumvi adoption accelerates over coming quarters, as this would provide fundamental support for a sustained recovery in the company's valuation metrics.
What people are saying
Follow the TGTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' 50/200-day trend indicator for TGTX shifted from uptrend to mixed during the week, suggesting a potential loss of momentum in the stock's recent advance. Despite this technical change, the current valuation verdict remains Undervalued, indicating the stock may still offer value at present price levels relative to fundamentals. The shift to mixed trend status warrants continued monitoring to determine whether the uptrend may resume or transition further.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TGTX's quality grade declined from C to D this week, reflecting a deterioration in the company's derived indicators as tracked by TickrTrends. Despite this downward shift in quality assessment, the stock maintains an undervalued valuation verdict within the Healthcare sector.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TGTX stock undervalued?
TGTX does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is TGTX's TickrTrends verdict?
TGTX is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does TGTX compare to other Healthcare stocks?
TGTX ranks #129 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TGTX overbought or oversold?
TGTX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does TGTX report earnings next?
TGTX's next earnings report is scheduled for 2026-11-02, per the published earnings calendar.
Does TGTX usually beat earnings estimates?
Over its last 8 reported quarters TGTX beat the consensus estimate 1 times and missed 7 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TGTX?
Of 8 analysts covering TGTX, 7 rate it a buy, 0 a hold and 1 a sell - buy-leaning, with a consensus price target of $69.7 (+29.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.